Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 10/11/17 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
59 | |
| 10/11/17 | 8-K | Current report filing |
|
35 | |
| 10/10/17 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
30 |
| 10/05/17 | 8-K | Current report filing |
|
7 | |
| 10/02/17 | DEF 14A | Definitive proxy statements |
|
24 | |
| 09/20/17 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
22 | |
| 09/08/17 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
59 | |
| 09/08/17 | 8-K | Current report filing |
|
66 | |
| 09/06/17 | 8-K | Current report filing |
|
6 | |
| 08/25/17 | 8-K | Current report filing |
|
4 |
